Lysosomal failure now sits near the center of neurodegenerative biology
Genetic studies have moved the lysosome from a housekeeping organelle to a core determinant of neuronal survival. In disorders defined by slowly accumulating protein aggregates, the logic is hard to ignore: if cells cannot clear damaged proteins, lipids, and membrane debris, vulnerable neurons are left to metabolize their own waste. The resulting dysfunction is not confined to one disease label. It cuts across Parkinson disease, Alzheimer disease, frontotemporal dementia, and amyotrophic lateral sclerosis, all of which share at least part of the same endolysosomal breakdown.
The review ties that biology to a broader point: lysosomes do far more than digest cargo. They regulate nutrient sensing, lipid metabolism, membrane repair, and neuroinflammatory signaling. In other words, impaired lysosomal biology can damage neurons through several routes at once, not just through failed waste disposal. A cell that loses lysosomal control also loses a major signaling hub.
One sentence captures the clinical gravity of the entire field: lysosomal dysfunction is not a side pathway in neurodegeneration; it is one of the most credible mechanistic engines behind it.
Parkinson disease carries the strongest genetic signal
The most robust evidence for endolysosomal involvement comes from Parkinson disease. A substantial proportion of PD-associated genes encode proteins with lysosomal roles, and two of the best-known genetic factors, GBA1 and LRRK2, now sit directly in the therapeutic crosshairs of clinical trials. That is important because it links human genetics, intracellular trafficking biology, and translational drug development in the same disease framework.
The review identifies several layers of lysosomal impairment in PD, including defects in lysosomal acidification, protease activity, trafficking, motility, membrane integrity and repair, and autophagy. Each defect can plausibly accelerate α-synuclein accumulation. If acidification is inadequate, degradative enzymes work less efficiently. If trafficking is disrupted, cargo reaches the lysosome late or not at all. If the membrane is unstable, lysosomal contents can leak and amplify cellular injury. The path from gene variant to neuron loss therefore does not require a single catastrophic event; incremental failure at multiple checkpoints is enough to push susceptible neurons toward degeneration.
Endolysosomal trafficking defects are reshaping Alzheimer disease thinking
In Alzheimer disease, the emphasis shifts toward trafficking rather than protease loss alone. Endolysosomal transport defects are implicated in disease pathogenesis, and deficiency of SORLA is singled out as a potentially key regulator of cargo movement through the endolysosomal system, including trafficking of amyloid precursor protein. This matters because amyloid biology is not only about production; it is also about where proteins travel inside the cell and whether they are routed for degradation or misprocessing.
A trafficking defect can alter the fate of amyloid precursor protein long before plaques become visible in tissue. If the sorting machinery fails, substrate handling becomes inefficient, and the system shifts toward intracellular congestion. In a long-lived neuron, even modest errors in recycling and sorting can have cumulative consequences. The review’s framing makes a strong case that Alzheimer disease should be read, in part, as a disorder of intracellular logistics.
Autophagy genes tie ALS and FTD to the same cellular clearance system
The connection is equally strong in amyotrophic lateral sclerosis and frontotemporal dementia, where multiple associated genes encode proteins with key roles in autophagy. That genetic pattern matters because autophagy is one of the principal routes by which neurons dispose of damaged organelles and aggregated proteins. When autophagic regulation fails, the cell loses a mechanism that is especially important in neurons, which rarely divide and therefore cannot dilute intracellular damage through cell turnover.
This shared biology helps explain why ALS and FTD, despite different clinical presentations, can converge on related intracellular failure modes. Protein handling, vesicular trafficking, and lysosomal degradation are not peripheral cellular chores. They are essential to maintaining axonal transport, synaptic function, and long-term neuronal viability. Once those systems falter, the clinical phenotype may differ, but the underlying stress on the cell can be strikingly similar.
Progranulin points to a tangible therapeutic axis in FTD
Among the lysosomal pathways discussed in the review, progranulin stands out because it contributes to lysosomal homeostasis through multiple mechanisms and is already being targeted with augmentation strategies in clinical trials for FTD. The biological appeal is straightforward. Restoring progranulin may help stabilize the lysosomal environment, improve degradative capacity, and reduce the downstream accumulation of toxic material.
Progranulin haploinsufficiency has also been linked to features of neuronal ceroid lipofuscinosis, reinforcing the idea that insufficient lysosomal support can produce a broader neurodegenerative phenotype than one syndrome alone. The therapeutic implication is practical: a disease-modifying strategy may need to restore basic cellular clearance capacity, not only silence a single toxic protein species.
Why lysosomes have become a translational target
The review’s central message is not simply that lysosomes are involved in neurodegeneration. It is that they sit at a convergence point for genetics, trafficking, metabolism, and inflammation. That makes them unusually attractive drug targets, but it also complicates therapy. A single intervention may not fix every downstream defect if one patient’s disease is driven more by acidification problems, another by trafficking failure, and another by impaired membrane repair.
Even so, the therapeutic logic is stronger now than it has ever been. When a pathway is repeatedly implicated across multiple disorders and supported by human genetics, it becomes difficult to dismiss as an epiphenomenon. The current challenge is to translate that biology into interventions that reach the relevant cellular compartment, hit the right stage of the disease process, and preserve neuronal function before irreparable damage accumulates.
For now, the field is left with a precise, testable premise: neurodegenerative diseases may differ at the bedside, but many of them share a common intracellular failure in lysosomal maintenance and cargo disposal. The next wave of trials will determine whether correcting that failure changes the course of disease, rather than merely describing it in finer detail.